# A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02420262` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02420262](<https://clinicaltrials.gov/study/NCT02420262>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02420262

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

## Technical summary

Registry record NCT02420262. Randomized; no masking; primary purpose treatment. Start 2015-07-26 (actual); primary completion 2016-10-05 (actual). Results posted on 2017-12-07.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 506 participants (enrolled count; ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Started: 2015-07-26 (actual) (ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Primary completion: 2016-10-05 (actual) (ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Completion: 2016-10-05 (actual) (ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Results first posted: 2017-12-07 (ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; Czechia; France; Greece; Hungary; Israel; Mexico; Russia; Slovakia; Spain; Türkiye (ClinicalTrials.gov record NCT02420262, source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02420262-2018-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/liraglutide
- Intervention (Drug): insulin glargine
- Intervention (Drug): insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial (`cardio:pubmed-29483185`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial (`cardio:pubmed-32107930`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6f12307d1ecc02033d2cbe6186b63afd6df1af188209b9230d7ebd124411f7a1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
